Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference
06 September 2022 - 9:00PM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose
mission it is to develop medicines that meaningfully improve and
extend the lives of patients facing deadly diseases, today
announced that Mike Sherman, Chief Executive Officer, will
present a pre-recorded corporate presentation at the H.C.
Wainwright 24th Annual Global Investment Conference made available
on Monday, September 12, 2022 at 7:00 a.m. ET.
An audio webcast of the presentation will be available on the
Investor Relations section of Chimerix's website at
ir.chimerix.com, where it will be archived for approximately 90
days.
About Chimerix
Chimerix is a biopharmaceutical company with a mission to
develop medicines that meaningfully improve and extend the lives of
patients facing deadly diseases. The Company’s most advanced
clinical-stage development program, ONC201, is in development for
H3 K27M-mutant glioma.
CONTACT:Investor
Relations: Michelle
LaSpaluto919 972-7115ir@chimerix.comWill O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024